This year (at ADLM) I had the chance to verify a old thesis about the role of Specialists in the expansion of diagnostics. Spot on!

It came from looking at the market. Put all the specialist areas of diagnostics together and they add up to a remarkable part of the industry. Yet the story we usually tell is about the opposite — bigger integrated systems, consolidation, automation, productivity. After three days on the floor, I came back convinced both things are happening at once.

On one side, laboratories keep consolidating. The pressure to do more with fewer people is real, and the industry answers with larger platforms, integrated automation, smarter workflows. On the other side, I kept meeting companies that had chosen the opposite path. They aren’t trying to cover the whole laboratory. They’re trying to understand one clinical need better than anyone else.

Specialization can take several forms — around a technology, a workflow, a piece of software. Those are real stories, but not this one. Here I mean the companies that organize themselves around serving a specific clinical need in depth.

The established ones are already well known. Werfen never needed to become another core lab company — it built a global business around related specialist areas: acute care, autoimmunity, transfusion, hemostasis. Euroimmun built its name on deep expertise in autoimmunity and infectious disease long before it became part of Revvity . Both proved specialization isn’t a niche. It’s a sound long-term strategy.

What caught me at ADLM was the next generation, going narrower still. Burning Rock Dx isn’t really selling sequencing — it’s building a company around precision oncology. Labsystems Diagnostics Oy isn’t trying to be a general supplier — it’s building around newborn screening. And in sepsis I didn’t find one company trying to own the field; I found a small peloton — Cytovale , Immunexpress Inc. , @LoopDx — all coming at the same clinical problem from different scientific directions. Their identity isn’t a platform. It’s the problem they’re trying to solve.

Underneath all of it is the same sequence, and it always runs in the same order. A clinical need goes unmet. The laboratories, closest to the patient, start looking for a way through. And the industry turns that search into something real at scale. An unmet need, a solution found at the bench, an opportunity for a company to build on. That triad is the engine — it’s what drives diagnostics forward, and it always starts with medicine, never with the machine.

Here’s the lesson I took from it. The triumph of specialists isn’t about beating the large integrated companies — the opposite, in fact. The industry majors remain essential to how a modern laboratory runs. The point is that you no longer have to become one of them to build a successful diagnostics company. Get genuinely good at solving an important clinical problem, and there’s room for you. If you are building a specialist company, or backing one, that is worth holding onto: the need is real, it is permanent, and it does not require you to win the whole laboratory to matter. It asks you to be indispensable in one thing.

And a word for the specialists themselves — the people, not the companies. Behind every one of these firms and every specialist laboratory are individuals who chose depth over breadth, who spent years becoming the person who understands one hard problem better than almost anyone. That choice rarely gets the spotlight the big platforms do. It should. They are the reason the whole thing moves.

One more thing struck me: the specialists are changing. The earlier generation built around broad disciplines — hemostasis, microbiology, autoimmunity. Today’s build around much narrower needs: precision oncology, newborn screening, women’s health, sepsis. The unit of specialization is getting smaller. Not because the industry is fragmenting — because medicine keeps asking more precise questions, and diagnostics keeps finding ways to answer them.

That was one of the strongest messages I took from the week. While one part of the industry consolidates laboratories and improves productivity, another keeps expanding what diagnostics can actually do for patients. Both will continue. And if ADLM is any indication, the triumph of specialists is far from over.